Cefodizime is a new expanded-spectrum cephalosporin for parenteral use which possesses a broad antibacterial spectrum and potent antibacterial activity and is stable against most ␤-lactamases. The aim of this study was to assess the pharmacokinetics of cefodizime, administered intravenously, over the dose range of 0.5 to 3.0 g in healthy volunteers. Concentrations of cefodizime in the serum and urine were determined by highperformance liquid chromatography. The area under the concentration-time curve from 0 h to infinity and the amount of drug excreted in urine from 0 to 34 h increased in a linear, dose-dependent manner with increasing doses of antibiotic from 0.5 to 3.0 g. Mean concentrations of cefodizime in plasma at the end of infusion increased from 97 to 440 mg liter ؊1 over the dose range 0.5 to 3.0 g and displayed a slight deviation from linearity at doses in excess of 2.0 g. Total plasma clearance (3.11 liters h ؊1 ), volume of distribution at steady state (10.5 liters), terminal elimination half-life (3.3 h), and renal clearance (1.91 liters h ؊1 ) remained constant over the doses administered. Cefodizime was well tolerated in this study.
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Cefodizime is a new expanded-spectrum cephalosporin for parenteral use which possesses a broad antibacterial spectrum and potent antibacterial activity and is stable against most ␤-lactamases (5). In addition, it acts synergistically with the host immune system (8, 9) .
It has been established that there is a linear relationship between the intravenous dose of cefodizime (range, 0.5 to 2.0 g) and the following pharmacokinetic parameters: initial concentration in serum, area under the serum concentration-time curve from 0 h to infinity (AUC 0-ϱ ), and recovery of cefodizime in the urine over 48 h (4) . At high concentrations of cefodizime in plasma (Ͼ180 mg liter Ϫ1 ), however, a saturation of the binding of cefodizime to plasma albumin has been observed (1) . These high concentrations were observed after a 2.0-g dose for a very short period after infusion. Defining the relationship between the dose and pharmacokinetic parameters of cefodizime over a more extensive dose range was therefore of interest. The aim of this study was to assess the pharmacokinetics of cefodizime, administered intravenously, over the dose range of 0.5 to 3.0 g in healthy volunteers.
MATERIALS AND METHODS
Subjects and study design. This study was an open, randomized, Latin square crossover study. Twelve healthy, male volunteers aged 18 to 40 years (mean age, 22.3 years), with a mean height of 181 Ϯ 1 cm (range, 175 to 188 cm) and a mean weight of 71 Ϯ 2 kg (range, 60 to 81 kg), were enrolled in the study. Informed written consent was obtained before enrollment. Within the 2 weeks prior to the first dose of cefodizime, a clinical history was taken and a physical examination, including an electrocardiogram, was performed. The following laboratory tests were undertaken: full blood, differential, and platelet count; prothrombin time; and standard biochemical parameters. The results of all of the clinical investigations had to be normal for the subject to be enrolled in the study.
Each volunteer fasted overnight before receiving a dose (0.5, 1.0, 2.0, or 3.0 g) of cefodizime (batch 75CN23; Roussel Uclaf, Romainville, France) by a 5-min intravenous infusion. All subjects were admitted to the Clinical Pharmacology Department, CEMAX, for the monitoring period following each dose.
Eighteen venous-blood and eight urine samples were obtained from each subject during the 34-h monitoring period. Blood samples were obtained prior to dosing and at 5 (end of infusion), 10, 20, 30, and 45 min and 1, 2, 3, 4, 6, 8, 10, 12, 15, 24, 28, and 34 h after the start of the infusion. Urine samples were collected over the following periods: predose, 0 to 2, 2 to 4, 4 to 6, 6 to 10, 10 to 15, 15 to 24, and 24 to 34 h.
There was a washout period of 7 days between administrations of the antibiotic. The clinical and physical examinations as well as the laboratory tests were repeated at the end of the study, after the fourth dose of cefodizime.
Assay methods. (i) Plasma. The concentration of cefodizime in the plasma samples was determined by high-pressure liquid chromatography (HPLC) with UV detection at 300 nm after solid-phase extraction. A sample volume of 0.25 ml was spiked with an internal standard (uvitic acid) and deproteinated with 2 volumes of methanol. After centrifugation, the mixture was forced through a solid-phase extraction microcolumn filled with a SAX modified silica, which retains cefodizime and the internal standard by anion exchange. The microcolumn was then washed with water. Cefodizime and the internal standard were eluted with 0.5 ml of 1 M sodium chloride. After the addition of 0.5 ml of water, 0.5 ml was injected into the chromatographic system. The reverse-phase column was Bondapak C 18 , 10 m (diameter, 3.9 mm; length, 300 mm; Waters). A mixture of acetonitrile and citrate buffer (0.1 M, pH 4.0), 14:86 (vol/vol), was used as the mobile phase. The flow rate was 1.5 ml min
Ϫ1
. The retention times of cefodizime and the internal standard were, respectively, 13 and 9.5 min. The calibration range was 0.05 to 2.0 mg liter
. The limit of quantification was 0.020 mg liter Ϫ1 for a sample volume of 0.25 ml. In this study, plasma samples with concentrations of Ͼ2.0 mg liter Ϫ1 were diluted 1:10, 1:20, 1:100, or 1:500 with blank human plasma.
The concentrations of the quality control samples were 0.1, 0.4, 1.6, 8, 40, and 160 mg liter
. The coefficients of variation of the assays in this study were estimated from the results obtained with the controls for each concentration; they ranged between 3.2 and 7.1%. The deviation between the means of the measured concentrations and the theoretical concentrations ranged between Ϫ9.0 and Ϫ0.4%.
(ii) Urine. The cefodizime assay used for the urine samples was similar to that used for the plasma samples with the following differences. Before solid-phase extraction, the urine samples (0.1 ml) were spiked with the internal standard and diluted 1:10 in acetate buffer (0.1 M, pH 5.0). The HPLC mobile phase was acetonitrile-citrate buffer (13:87).
The limit of quantification was 1 mg liter Ϫ1 for a sample volume of 0.1 ml. The calibration range was 2 to 100 mg liter
. The coefficients of variation of the assays in this study were estimated from the results obtained with the controls for each concentration; they ranged between 2.8 and 5.9%. The deviation between the means of the measured concentrations and the theoretical concentrations ranged between Ϫ1.4 and ϩ2.3%.
Data analysis. The plasma concentration-time curve from the end of infusion was constructed from the sum of the three exponential functions:
Coefficients (A, B, and C) and apparent rate constants of distribution and elimination (␣, ␤, and ␥) were determined by a least-squares nonlinear regression analysis (10) . Half-lives (t 1/2␣ , t 1/2␤ , and t 1/2␥ ) were calculated by dividing ln2 by the corresponding rate constant. Pharmacokinetic parameters (means Ϯ standard deviations) were subjected to a three-way analysis of variance to test subject, period, and dose effects. In cases in which the analysis of variance demonstrated a significant dose effect, the means of the parameters for each treatment were compared by Tukey's test. 
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Ninety percent confidence intervals (90% CI) for each point estimate (paireddose ratio) were calculated on ln-transformed data of dose-normalized C 5min (concentration of cefodizime in plasma at the end of infusion), AUC, and U values.
Regression analysis was carried out on C 5min , AUC 0-ϱ , and U 0-34 . When the regression was significant and the deviation from linearity was not significant, the slope and the intercept of the regression line were calculated and the intercept was compared with 0. When the intercept was not significantly different from 0 the regression line was forced through the origin.
RESULTS
C 5min , AUC 0-ϱ , and U 0-34 h increased in a linear, dosedependent manner with increasing doses of the antibiotic, apart from a slight deviation from linearity for C 5min at doses in excess of 2.0 g ( Fig. 1 through 5 ; Table 1 , and those for U ranged from 344 Ϯ 58 to 1,789 Ϯ 176 mg. t 1/2␣ , t 1/2␤ , t 1/2␥ , CL T , V ss , and CL R did not change significantly with increased doses ( Table 1) .
The analysis of variance did not demonstrate any significant differences between doses for the normalized values for AUC (P Ͼ 0.05). There were, however, significant differences between doses for normalized C 5min values (P ϭ 0.0004) and U values (P ϭ 0.044).
The 90% CIs were within 80 to 125% for the dose-normalized AUC, U, and C 5min values, except for the ratio of C 5min values for the 3.0-and 0.5-g doses and the ratio for the 3.0-and 1.0-g doses ( Table 2) .
The relationship between doses and C 5min , AUC 0-ϱ and U 0-34 are represented in Fig. 3 through 5 . Linear relationships were as follows: AUC ϭ 317.8 ϫ dose; U ϭ 690.9 ϫ dose. For C 5min there was no significant deviation from linearity but the intercept was significantly different from 0 (C 5min ϭ 136.7 ϫ dose ϩ 39.9).
The blood pressure, heart rate, respiratory rate, temperature, and electrocardiograph for each subject were all normal both at the initial visit and at the end of the study. Cefodizime was well tolerated by the volunteers.
DISCUSSION
This study demonstrated that the values for AUC, U and (except for doses above 2.0 g) C 5min for cefodizime were dose dependent in a linear manner over the dose range tested (0.5 to 3.0 g) when the antibiotic was administered intravenously to healthy male volunteers. These results are in agreement with, and extend, those obtained by Dagrosa and coworkers, who investigated the pharmacokinetics of cefodizime in healthy male volunteers after single-dose intravenous administration (dose range, 0.5 to 2.0 g) (4). The linear pharmacokinetics of cefodizime facilitate the prediction of the effects of dosage adjustments, for example, in patients with renal or hepatic impairment (6, 7) .
The results of this study confirm data published by Bryskier and coworkers, who obtained terminal elimination half-life values similar to those reported here, i.e., 3.23 to 3.49 h (3).
The deviation from linearity for C 5min at doses above 2.0 g was probably due to saturable protein binding. In vitro binding of cefodizime to serum proteins remained constant (Х89%) at concentrations below 180 mg liter , and 69% at 470 mg liter Ϫ1 (1, 2). Mean concentrations were above the saturation threshold for 5 min, 0.5 h, and 1.5 h after the administration of the 1.0-, 2.0-, and 3.0-g doses, respectively. The resulting increase in the unbound fraction of the compound was associated with an increase in V ss , but this was negligible compared with the kinetics of cefodizime during the monitoring period. This is confirmed by a nonsignificant difference between doses with respect to CL T and V ss .
Surprisingly, although saturable protein binding would be expected to lead to an increase in percent urinary excretion at the highest doses, calculation of the data shows an apparent decrease which is, however, not clearly dose related. Although the difference between values at the highest and lowest doses was statistically significant, the level of difference (13%) was low and the 90% CIs for the point estimates were within the 80-to-125% interval.
Moreover, the renal clearance was independent of the dose, and overall we conclude that the apparent difference in urinary excretion is of no clinical significance and is a fortuitous event.
A deviation from linearity, due to saturable protein binding, has also been described for ceftriaxone (11) (12) (13) . This phenomenon was observed at doses from 1.5 g. It was more marked than that observed with cefodizime because it was associated with a significant increase in both CL T and V ss .
The results of this study confirm that cefodizime displays a linear kinetic profile for the main pharmacokinetic parameters (AUC, U, CL T , CL R , V ss , and t 1/2␥ ) in the dose range of 0.5 to 3.0 g. The deviation from linearity of C 5min probably has limited clinical relevance.
Within the dose range tested, cefodizime was well tolerated.
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